Coherus Oncology, Inc. (NASDAQ: CHRS) is a Healthcare company (Biotechnology) with a market capitalization of $74M. The Maz Rating grades it against the other companies in its sector.
Coherus Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.48, Coherus Oncology, Inc. trades at 1.3x sales and 2.7x book value. Over the last twelve months it generated about $58M of revenue and a net loss of $163M. It runs a gross margin of 66.5%, an operating margin of -275.9% and a net margin of -252.0%. It shows return on equity of -239.6%, return on invested capital of -180.1% and a free cash flow yield of -331.5%. On the balance sheet: a debt-to-equity ratio of 2.75 and a current ratio of 1.47. Over the past 52 weeks the share price ranged from $0.43 to $2.62, with a beta of 1.03.
Coherus Oncology, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 14 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Coherus Oncology, Inc. (CHRS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 39.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 48.8% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 39.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 48.8% / 33% · Receivables / Mkt Cap (36m) 8.12% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 39.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 48.8% / 33.33% · Receivables / Mkt Cap (24m) 8.12% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 22.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 59.6% / 33.33% · Receivables / Avg Assets (4Q) 7.79% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 39.5% / 33.33% · (Cash+ST Inv) / Total Assets 48.9% / 33.33% · (Cash+Recv) / Total Assets 57.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Coherus Oncology, Inc. (CHRS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Coherus Oncology, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
Coherus Oncology, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.